Tuberc Respir Dis > Volume 71(3); 2011 > Article
Tuberculosis and Respiratory Diseases 2011;71(3):210-215.
DOI:    Published online September 1, 2011.
Imatinib-Mesylate Induced Interstitial Pneumonitis in Two CML Patients.
Tae Hoon Kim, Byung Gyu Kim, Sung Woo Cho, Sung Kyun Cho, Hyun Jung Kim, Young Jin Yuh, Sung Rok Kim
1Department of Internal Medicine, Sanggye-Paik Hospital, Inje University College of Medicine, Seoul, Korea.
2Department of Pathology, Sanggye-Paik Hospital, Inje University College of Medicine, Seoul, Korea.
Imatinib mesylate, a selective inhibitor of BCR-ABL kinase activity, has demonstrated significant clinical efficacy in the treatment of chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GISTs). It has become the standard of treatment for these diseases. Although the toxicity profile of imatinib is superior to that of interferon or other cytotoxic agents, some adverse events including edema, gastrointestinal toxicities and hematologic toxicities are commonly observed in the patients treated by imatinib. We present two cases of imatinib induced interstitial pneumonitis during the treatment of a chronic phase of CML.
Key Words: imatinib mesylate, Lung Diseases, Interstitial, Chronic Myeloid Leukemia

Article category

Browse all articles >


Browse all articles >

Editorial Office
101-605, 58, Banpo-daero, Seocho-gu (Seocho-dong, Seocho Art-Xi), Seoul 06652, Korea
Tel: +82-2-575-3825, +82-2-576-5347    Fax: +82-2-572-6683    E-mail:                

Copyright © 2024 by The Korean Academy of Tuberculosis and Respiratory Diseases. All rights reserved.

Developed in M2PI

Close layer
prev next